Mansour Iyad, Murugapandian Sangeetha, Tanriover Bekir, Thajudeen Bijin
Division of Nephrology, College of Medicine, The University of Arizona, Tucson.
Mayo Clin Proc Innov Qual Outcomes. 2023 Jun 30;7(4):276-290. doi: 10.1016/j.mayocpiqo.2023.04.009. eCollection 2023 Aug.
Therapeutic monoclonal antibodies (MAbs) have been one of the fastest growing drug classes in the past 2 decades and are indicated in the treatment of cancer, autoimmune disorders, solid organ transplantation, and glomerular diseases. The Food and Drug Administration has approved 100 MAbs between 1986 and 2021, and MAbs account for 20% of Food and Drug Administration's new drug approval every year. MAbs are preferred over traditional immunosuppressive agents because of their high specificity, reduced number of drug-drug interactions, and low toxicity, which make them a prime example of personalized medicine. In this review article, we provide an overview of the taxonomy, pharmacology, and therapeutic applications of MAbs in glomerular diseases. We searched the literature through PubMed using the following search terms: , and limited our search to years 2018-2023. We selected peer-reviewed journal articles with an evidence-based approach, prioritizing randomized control trials in specific glomerular diseases, if available. Advances in the MAb field have resulted in a significant paradigm shift in targeted treatment of immune-mediated glomerular diseases, and multiple randomized control trials are currently being conducted. Increased recognition is critical to expand their use in experimental research and personalized medicine.
治疗性单克隆抗体（MAbs）在过去20年中一直是增长最快的药物类别之一，被用于治疗癌症、自身免疫性疾病、实体器官移植和肾小球疾病。1986年至2021年间，美国食品药品监督管理局（FDA）已批准了100种单克隆抗体，且单克隆抗体每年占FDA新药批准数量的20%。由于单克隆抗体具有高特异性、较少的药物相互作用以及低毒性，因此相较于传统免疫抑制剂更受青睐，这使其成为个性化医疗的典范。在这篇综述文章中，我们概述了单克隆抗体在肾小球疾病中的分类、药理学及治疗应用。我们通过PubMed使用以下检索词搜索文献，并将搜索范围限定在2018 - 2023年。我们采用循证方法选择同行评审的期刊文章，如有可能，优先选择特定肾小球疾病的随机对照试验。单克隆抗体领域的进展已导致免疫介导性肾小球疾病靶向治疗发生重大范式转变，目前正在进行多项随机对照试验。提高认知度对于扩大其在实验研究和个性化医疗中的应用至关重要。
